Nephrol Dial Transplant (2004) 19: 553-560
Nephrol Dial Transplant Vol. 19 No. 3 (c) ERA-EDTA 2004; all rights reserved
Original Article
In vitro treatment of dendritic cells with tacrolimus: impaired T-cell activation and IP-10 expression
1Department of Nephrology, 2Department of Dermatology and 3Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria
Correspondence and offprint requests to: Christine Heufler, Dept of Dermatology, University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. Email: christine.heufler{at}uibk.ac.at
Background. High doses (10–6–10–8 M) of tacrolimus (FK506) were reported to induce a type-2 T-helper cell (Th2)-promoting function in developing dendritic cells (DC). We used a therapeutic dose (2.4 x 10–9 M) of tacrolimus to investigate its effect on human monocyte-derived DC.
Methods. Using untreated and treated immature and mature DC we compared T cell-activating capacity, surface marker expression, T cell and DC cytokine profile and transcription of genes coding for a panel of DC function-related molecules.
Results. Tacrolimus-treated mature DC had reduced T-cell stimulatory capacity. Although interleukin (IL)-12 production of DC was impaired, they did not promote Th2 development as T cells activated by tacrolimus-treated DC produced less interferon (IFN)-
, IL-4 and IL-10. The up-regulation of the T-cell activation marker CD69 and the production of IL-2 were impaired. In addition, tacrolimus-treated DC produced less IP-10 (CXCL10), which is known to be involved in allograft rejection. Other molecules related to DC function remained unchanged.
Conclusions. Tacrolimus treatment reduces the ability of DC to stimulate T cells and the impaired production of DC-derived IP-10 (CXCL10) and IL-12 might play a role in the immunosuppressive action of tacrolimus.
Keywords: chemokines; dendritic cells; immunosuppression; T lymphocytes; transplantation
The authors wish it to be known that, in their opinion, the first two authors contributed equally to this work.